MarketCapExport financials
DermTech (DMTK)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
DermTech Financial Ratios 2023-2011 | DMTK
Brief overview of DermTech's valuation multiples
Ratios are assessed across five available annual reports in the 2019–2023 interval.
The current valuation set is P/S 2.77x (median 25.72x), P/B 0.74x (median 1.61x). Valuation is roughly 71.6% below five-year reference levels. The discount may reflect opportunity or higher perceived risk.
Current measures of operating quality are ROE -176.5%, ROA -82.7%, ROCE -181.4%. Losses and negative capital returns make ordinary P/E-like references unstable or inapplicable.
Price, earnings and growth produce a PEG of 0.15x. A value below one indicates moderate pricing relative to expected growth.
The time from paying for inputs to receiving cash rose from -32.2 days to 66.7 days. Cash turnover slowed.
Overall assessment
DermTech's discount may reflect genuine profitability issues rather than market inefficiency alone.
Annual Financial Ratios DermTech
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-0.4 | -1.0 | -4.7 | -19.1 | -4.3 | -9.0 | 291.4 | - | - | - | - | - | - |
P/S |
2.8 | 8.1 | 31.3 | 118.2 | 25.7 | 37.0 | - | - | - | - | - | - | - |
EPS |
-3.1 | -3.9 | -2.7 | -2.1 | -2.9 | -2.3 | -0.0 | - | - | - | - | - | - |
EV (Enterprise Value) |
70.4 M | 109 M | 212 M | 680 M | 77.5 M | 96.5 M | 73.5 M | 112 K | - | - | - | - | - |
EBITDA per Share |
-3.17 | -3.93 | -2.68 | -2.08 | -2.5 | -1.92 | - | - | - | - | - | - | - |
EV/EBITDA |
-0.7 | -0.9 | -2.7 | -19.3 | -4.4 | -11.4 | -1224958.9 | -40.9 | - | - | - | - | - |
PEG |
-0.03 | - | - | -0.85 | 0.15 | -0.0 | - | - | - | - | - | - | - |
P/B |
0.7 | 0.9 | 1.6 | 11.3 | 7.3 | -16.9 | 3303.0 | - | - | - | - | - | - |
P/CF |
-0.6 | -1.2 | -6.0 | -24.3 | -4.9 | -11.9 | 33432.1 | - | - | - | - | - | - |
ROE % |
-176.45 | -88.16 | -34.10 | -58.99 | -169.72 | 186.82 | -31.27 | - | - | - | - | - | - |
ROA % |
-82.74 | -57.74 | -31.55 | -52.27 | -110.54 | -176.62 | 129.25 | - | - | - | - | - | - |
ROCE % |
-181.44 | -89.28 | -33.70 | -56.28 | -104.22 | 2644.02 | 0.01 | -12.27 | - | - | - | - | - |
Current Ratio |
1.9 | 2.9 | 13.3 | 8.8 | 2.9 | 0.5 | 1.1 | 1.2 | - | - | - | - | - |
DSO |
80.6 | 100.8 | 82.1 | 67.0 | 68.4 | 43.3 | - | - | - | - | - | - | - |
DIO |
33.5 | 29.4 | 10.1 | 4.2 | 4.1 | 2.8 | - | - | - | - | - | - | - |
DPO |
47.4 | 69.7 | 76.9 | 97.1 | 104.7 | 19.9 | - | - | - | - | - | - | - |
Operating Cycle |
114.2 | 130.2 | 92.2 | 71.2 | 72.5 | 46.1 | - | - | - | - | - | - | - |
Cash Conversion Cycle |
66.7 | 60.5 | 15.3 | -25.9 | -32.2 | 26.3 | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios DermTech
| 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.58 | -0.57 | -0.99 | -1.02 | - | -0.96 | -0.99 | -1.01 | - | -0.68 | -0.59 | -0.55 | - | -0.5 | -0.58 | -0.53 | - | -0.8 | -0.12 | -0.02 | -0.05 | -0.01 | -0.02 | -0.01 | -0.01 | -0.02 | -0.01 | -0.02 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
-0.58 | -0.54 | -0.98 | -1.03 | - | -0.97 | -0.99 | -1.01 | - | -0.68 | -0.59 | -0.49 | - | -0.49 | -0.58 | -0.53 | - | -0.86 | -0.11 | -0.03 | -0.06 | -0.02 | -0.02 | -0.01 | -0.02 | -0.02 | -0.01 | -0.02 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-141.03 | -109.56 | -99.90 | -79.08 | -49.92 | -57.91 | -45.74 | -35.04 | -20.25 | -38.22 | -46.21 | -50.32 | -44.46 | -74.76 | -56.75 | -31.90 | -21.39 | -30.79 | 4.55 | 9.44 | -0.07 | -21.94 | -22.04 | -27.61 | 1082.82 | 1113.95 | -0.63 | 1109.79 | - | - | - | -0.13 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-70.95 | -66.35 | -66.14 | -58.74 | -41.08 | -48.54 | -39.91 | -31.91 | -19.34 | -35.80 | -42.91 | -46.43 | -40.75 | -64.62 | -48.15 | -33.30 | -23.57 | -14.68 | 9.36 | 9.53 | 9.21 | 0.49 | 0.49 | 0.30 | 126.87 | 0.17 | -0.02 | 126.55 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-144.75 | -112.36 | -101.95 | -80.30 | -50.42 | -58.49 | -46.08 | -34.60 | -19.76 | -37.75 | -45.68 | -49.71 | -44.49 | -77.09 | -72.60 | -59.76 | -49.25 | -43.07 | -12.42 | -1.02 | 1.70 | 7.60 | 7.45 | 9.10 | -461.65 | -2.09 | -0.45 | -471.19 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
1.6 | 2.1 | 2.3 | 2.5 | 2.9 | 5.0 | 5.8 | 6.7 | 13.3 | 15.0 | 32.9 | 32.3 | 8.8 | 11.9 | 11.2 | 13.5 | 2.9 | 4.7 | 26.1 | 28.7 | 0.5 | 28.9 | 28.9 | 28.7 | 28.9 | 28.9 | 28.7 | 1.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
72.4 | 87.0 | 86.6 | 103.2 | - | 154.0 | 118.1 | 108.5 | - | 75.3 | 59.1 | 60.3 | - | 57.9 | 102.5 | 54.4 | - | 120.6 | 101.1 | 96.5 | - | 41.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
29.5 | 31.1 | 33.6 | 39.8 | - | 34.9 | 30.6 | 16.0 | - | 14.5 | 13.5 | 8.7 | - | 5.6 | 5.0 | 4.2 | - | 4.6 | 4.7 | 5.4 | - | 2.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
52.7 | 49.1 | 46.0 | 48.9 | - | 47.6 | 34.0 | 57.2 | - | 72.5 | 82.2 | 95.6 | - | 46.3 | 75.0 | 120.2 | - | 153.0 | 214.0 | 136.2 | - | 19.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | 118.1 | 120.2 | 142.9 | - | 188.9 | 148.7 | 124.5 | - | 89.8 | 72.6 | 69.0 | - | 105.1 | 166.6 | 68.6 | - | 113.9 | 105.7 | 101.8 | - | 43.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | 69.0 | 74.2 | 94.0 | - | 141.3 | 114.7 | 67.3 | - | 17.3 | -9.6 | -26.6 | - | 15.8 | 67.2 | -52.1 | - | -74.5 | -108.3 | -34.3 | - | 24.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company DermTech, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Diagnostics research industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Anixa Biosciences
ANIX
|
$ 2.81 | 1.63 % | $ 91.2 K |  USA |
 |
Biodesix
BDSX
|
$ 27.49 | 1.95 % | $ 208 M | USA |
 |
Biomerica
BMRA
|
$ 2.4 | 5.96 % | $ 7 M | USA |
 |
BioNano Genomics
BNGO
|
$ 1.35 | 10.66 % | $ 7.35 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
$ 11.67 | 5.68 % | $ 123 M |  China |
 |
Bioventus
BVS
|
$ 13.22 | 1.85 % | $ 881 M | USA |
 |
CareDx, Inc
CDNA
|
$ 52.37 | 4.21 % | $ 2.79 B | USA |
 |
Celcuity
CELC
|
$ 83.55 | 0.12 % | $ 3.91 B | USA |
 |
Co-Diagnostics
CODX
|
$ 1.14 | 1.79 % | $ 1.52 M | USA |
 |
Charles River Laboratories International
CRL
|
$ 269.48 | 0.06 % | $ 13.4 B | USA |
 |
Castle Biosciences
CSTL
|
$ 33.22 | 2.74 % | $ 963 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
$ 239.32 | 1.83 % | $ 26.6 B | USA |
 |
Danaher Corporation
DHR
|
$ 202.7 | 1.28 % | $ 144 B | USA |
 |
DarioHealth Corp.
DRIO
|
$ 7.1 | 2.31 % | $ 28.3 M |  Israel |
 |
Fulgent Genetics
FLGT
|
$ 20.56 | 0.54 % | $ 633 M | USA |
 |
Guardant Health
GH
|
$ 165.87 | 5.39 % | $ 20.8 B | USA |
 |
ICON Public Limited Company
ICLR
|
$ 169.34 | 0.02 % | $ 13.3 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
$ 509.72 | 0.99 % | $ 41 B | USA |
 |
Illumina
ILMN
|
$ 207.94 | 0.72 % | $ 32.2 B | USA |
 |
IQVIA Holdings
IQV
|
$ 264.81 | 1.16 % | $ 45.5 B | USA |
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M |  Canada |
 |
Laboratory Corporation of America Holdings
LH
|
$ 314.56 | 0.95 % | $ 26.2 B | USA |
 |
Lantheus Holdings
LNTH
|
$ 100.27 | 0.02 % | $ 6.77 B | USA |
 |
Medpace Holdings
MEDP
|
$ 591.17 | 0.62 % | $ 17.1 B | USA |
 |
Mettler-Toledo International
MTD
|
$ 1 287.94 | 1.01 % | $ 26.5 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
$ 3.74 | 9.36 % | $ 346 M | USA |
 |
ENDRA Life Sciences
NDRA
|
$ 5.68 | 0.98 % | $ 4.47 M | USA |
 |
NeoGenomics
NEO
|
$ 18.27 | 5.51 % | $ 2.34 B | USA |
 |
Neogen Corporation
NEOG
|
$ 11.87 | 0.72 % | $ 2.58 B | USA |
 |
National Research Corporation
NRC
|
$ 22.14 | 4.83 % | $ 496 M | USA |
 |
Natera
NTRA
|
$ 339.13 | 3.1 % | $ 46.4 B | USA |
 |
OPKO Health
OPK
|
$ 1.55 | 0.38 % | $ 1.16 B | USA |
 |
Pacific Biosciences of California
PACB
|
$ 1.36 | 4.23 % | $ 408 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
$ 25.15 | 2.28 % | $ 23.8 B |  Niderland |
 |
Personalis
PSNL
|
$ 16.3 | 0.52 % | $ 1.45 B | USA |
 |
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | USA |
 |
Senseonics Holdings
SENS
|
$ 8.88 | 1.95 % | $ 371 M | USA |
 |
Neuronetics
STIM
|
$ 2.89 | 5.61 % | $ 191 M | USA |
 |
Thermo Fisher Scientific
TMO
|
$ 611.62 | 0.3 % | $ 231 B | USA |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | USA |
 |
Twist Bioscience Corporation
TWST
|
$ 136.05 | 6.94 % | $ 8.14 B | USA |
 |
VolitionRx Limited
VNRX
|
$ 0.31 | 0.34 % | $ 39 M |  Singapore |
 |
Waters Corporation
WAT
|
$ 407.54 | 1.67 % | $ 24.3 B | USA |
 |
Heska Corporation
HSKA
|
- | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | USA |
 |
Syneos Health
SYNH
|
- | - | $ 4.46 B | USA |
 |
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | USA |
 |
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K | Israel |
 |
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M |  Britain |
 |
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | USA |